Iryna Pykalo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iryna Pykalo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Sergii Dvoriak
Affiliation Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
3 shared publicationsDaniel J. Bromberg
Yale School of Medicine, Department of Medicine, Section of Infectious Diseases, Center for Interdisciplinary Research on AIDS, and Yale School of Public Health, Yale University, New Haven, Connecticut (D.J.B.)
2 shared publicationsDenise Esserman
Center for Interdisciplinary Research on AIDS and Yale School of Public Health, Yale University, New Haven, Connecticut (D.E.)
2 shared publicationsFrederick L. Altice
Yale Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States of America
2 shared publicationsKostyantyn Dumchev
Affiliation European Institute of Public Health Policy, Kyiv, Ukraine
2 shared publications- Myroslava Filippovych
Affiliation Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341182
Holding the line: Provider and patient perspectives on Medications for Opioid Use Disorder continuity during the war in Ukraine
Background: Ukraine has one of the highest rates of opioid use in Eastern Europe, with an estimated 346,900 people who inject drugs (PWID). Medications for opioid use disorder (MOUD) are critical for reducing opioid-related harms, including HIV transmission. However, the full-scale Russian invasion of Ukraine in February 2022 significantly disrupted MOUD services. Although the Ukraine public health system has worked to address displacement and disruptions, the ongoing armed conflict exacerbated long-standing structural challenges in the Ukrainian addiction treatment system, leading to displacement of patients and providers, damage to infrastructure, and interruptions in medication supply. Methods: This qualitative study explores the barriers and facilitators to MOUD access and retention during wartime. Semi-structured interviews were conducted between September and November 2022 with 10 MOUD patients who had been displaced due to the war and 7 healthcare providers in three Ukrainian cities (Lviv, Poltava, Ivano-Frankivsk) that received large numbers of internally displaced persons (IDPs). All patients had been enrolled in MOUD prior to the invasion and continued treatment in their new locations. Data were analyzed using the Rapid Assessment Procedure (RAP) framework to identify thematic patterns across settings and perspectives. Results: Both providers and patients reported a range of systemic, logistical, and emotional challenges affecting continuity of care. Key barriers included loss of medical records, reduced dosing due to medication shortages, delayed access for new patients, and financial hardship. Providers also described increased workloads, staff shortages, and lack of emergency preparedness. Patients often relied on peers, non-governmental organisations (NGOs), and informal channels to locate MOUD sites. Despite adversity, many patients remained committed to treatment. Providers adopted flexible, sometimes unofficial practices to sustain care delivery. Conclusions: This study highlights the fragility but also resilience of MOUD services in a conflict setting. Findings emphasize the need for policy reforms that institutionalize emergency flexibility, strengthen referral systems, support frontline staff, and integrate peer and civil society support into the national MOUD strategy. Ensuring uninterrupted access to MOUD during crises is vital for public health and for protecting the rights of people who use drugs.
- 23 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341182
Open AccessHolding the line: Provider and patient perspectives on Medications for Opioid Use Disorder continuity during the war in Ukraine
Background: Ukraine has one of the highest rates of opioid use in Eastern Europe, with an estimated 346,900 people who inject drugs (PWID). Medications for opioid use disorder (MOUD) are critical for reducing opioid-related harms, including HIV transmission. However, the full-scale Russian invasion of Ukraine in February 2022 significantly disrupted MOUD services. Although the Ukraine public health system has worked to address displacement and disruptions, the ongoing armed conflict exacerbated long-standing structural challenges in the Ukrainian addiction treatment system, leading to displacement of patients and providers, damage to infrastructure, and interruptions in medication supply. Methods: This qualitative study explores the barriers and facilitators to MOUD access and retention during wartime. Semi-structured interviews were conducted between September and November 2022 with 10 MOUD patients who had been displaced due to the war and 7 healthcare providers in three Ukrainian cities (Lviv, Poltava, Ivano-Frankivsk) that received large numbers of internally displaced persons (IDPs). All patients had been enrolled in MOUD prior to the invasion and continued treatment in their new locations. Data were analyzed using the Rapid Assessment Procedure (RAP) framework to identify thematic patterns across settings and perspectives. Results: Both providers and patients reported a range of systemic, logistical, and emotional challenges affecting continuity of care. Key barriers included loss of medical records, reduced dosing due to medication shortages, delayed access for new patients, and financial hardship. Providers also described increased workloads, staff shortages, and lack of emergency preparedness. Patients often relied on peers, non-governmental organisations (NGOs), and informal channels to locate MOUD sites. Despite adversity, many patients remained committed to treatment. Providers adopted flexible, sometimes unofficial practices to sustain care delivery. Conclusions: This study highlights the fragility but also resilience of MOUD services in a conflict setting. Findings emphasize the need for policy reforms that institutionalize emergency flexibility, strengthen referral systems, support frontline staff, and integrate peer and civil society support into the national MOUD strategy. Ensuring uninterrupted access to MOUD during crises is vital for public health and for protecting the rights of people who use drugs.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 177-186
Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial
Opioid use disorder (OUD) drives high morbidity and mortality, but access to opioid agonist therapy (OAT) is limited in low- and middle-income countries. Integrating OAT into primary care may expand access and improve comorbidity management, although provider discomfort remains a barrier. To compare health care use among persons with OUD receiving methadone in specialty clinics versus primary care centers in Ukraine (January 2018 to December 2023). Two-group randomized controlled trial with 2:1 allocation to intervention and control. (ClinicalTrials.gov: NCT04927091). Thirteen cities in Ukraine: Cherkasy, Dnipro, Kramatorsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lviv, Mariupol, Mykolaiv, Odesa, Rivne, Sloviansk, and Zhytomyr. A total of 1459 adults with OUD (950 intervention, 509 control) initiating or receiving methadone. Methadone delivered in primary care aided with telementoring, an Extension for Community Healthcare Outcomes-like model that is adapted to the Ukraine context, versus standard specialty clinic care. Primary outcome: difference in composite quality health indicator (QHI) scores between groups at 24 months, representing access to 17 guideline-concordant services (9 primary care and 8 specialty care) received, assessed through surveys and ranging from 0 to 100. Secondary outcomes: domain-specific QHI scores and methadone treatment indicators. Participants in primary care settings achieved higher composite QHI scores than those in specialty clinics, with a mean difference of 9.1 percentage points (95% CI, 6.9 to 11.2 percentage points) at 24 months. Results were similar for primary care QHI (12.3 percentage points [CI, 9.0 to 15.6 percentage points]) and specialty care QHI (5.2 percentage points [CI, 0.2 to 10.3 percentage points]). Methadone retention among new patients at 24 months was 67.2% in primary care versus 64.7% in specialty clinics. Quality health indicators reflect health care use rather than health outcomes. Quality health indicators were equally weighted despite differing clinical significance. Integrating methadone treatment into primary care settings improves adherence to guideline-concordant health care without compromising methadone retention and treatment quality. National Institute on Drug Abuse.
- 1 February 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (2) , 177-186
Integrating Methadone Services Into Primary Care in Ukraine: Two-Year Outcomes From a Randomized Trial
Opioid use disorder (OUD) drives high morbidity and mortality, but access to opioid agonist therapy (OAT) is limited in low- and middle-income countries. Integrating OAT into primary care may expand access and improve comorbidity management, although provider discomfort remains a barrier. To compare health care use among persons with OUD receiving methadone in specialty clinics versus primary care centers in Ukraine (January 2018 to December 2023). Two-group randomized controlled trial with 2:1 allocation to intervention and control. (ClinicalTrials.gov: NCT04927091). Thirteen cities in Ukraine: Cherkasy, Dnipro, Kramatorsk, Kropyvnytskyi, Kryvyi Rih, Kyiv, Lviv, Mariupol, Mykolaiv, Odesa, Rivne, Sloviansk, and Zhytomyr. A total of 1459 adults with OUD (950 intervention, 509 control) initiating or receiving methadone. Methadone delivered in primary care aided with telementoring, an Extension for Community Healthcare Outcomes-like model that is adapted to the Ukraine context, versus standard specialty clinic care. Primary outcome: difference in composite quality health indicator (QHI) scores between groups at 24 months, representing access to 17 guideline-concordant services (9 primary care and 8 specialty care) received, assessed through surveys and ranging from 0 to 100. Secondary outcomes: domain-specific QHI scores and methadone treatment indicators. Participants in primary care settings achieved higher composite QHI scores than those in specialty clinics, with a mean difference of 9.1 percentage points (95% CI, 6.9 to 11.2 percentage points) at 24 months. Results were similar for primary care QHI (12.3 percentage points [CI, 9.0 to 15.6 percentage points]) and specialty care QHI (5.2 percentage points [CI, 0.2 to 10.3 percentage points]). Methadone retention among new patients at 24 months was 67.2% in primary care versus 64.7% in specialty clinics. Quality health indicators reflect health care use rather than health outcomes. Quality health indicators were equally weighted despite differing clinical significance. Integrating methadone treatment into primary care settings improves adherence to guideline-concordant health care without compromising methadone retention and treatment quality. National Institute on Drug Abuse.
- Open Access
- 26 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305072
Modes of HIV transmission among young women and their sexual partners in Ukraine
Background: Ukraine has the second-largest HIV epidemic in Europe, with most new cases officially attributed to heterosexual transmission. Indirect evidence suggested substantial HIV transmission from people who inject drugs (PWID) to their sexual partners. This study examined the extent of heterosexual HIV transmission between PWID and non-drug-using adolescent girls and young women (AGYW). Methods: A cross-sectional survey recruited AGYW diagnosed with heterosexually-acquired HIV between 2016 and 2019 in nine regions of Ukraine. AGYW were asked to identify and refer their sexual partners (‘Partners’), who subsequently underwent HIV testing, and, if positive, HCV testing. Both AGYW and Partners completed an interview assessing HIV risk behaviors prior to AGYW’s HIV diagnosis. Results: In August-December 2020, we enrolled 321 AGYW and 64 Partners. Among the Partners, 42% either self-reported IDU or were HCV-positive, indicating an IDU-related mode of HIV transmission. PWID Partners were more likely to report sexually transmitted infections (STI) and had lower educational levels. Of the 62 women who recruited at least one Partner, 40% had a PWID Partner. Within this subgroup, there was a higher prevalence of STIs (52% vs. 24%) and intimate partner violence (36% vs. 3%). Condom use was less common (52% vs. 38% reporting never use), and frequent alcohol or substance use before sex was higher (48% vs 30%) among AGYW with PWID Partner, although this difference did not reach statistical significance. Notably, 52% of women were aware of their Partners’ IDU. Conclusion: At least 40% of heterosexual transmission among AGYW in Ukraine can be linked to PWID partners. Intensified, targeted HIV prevention efforts are essential for key and bridge populations (PWID and their sexual partners), addressing the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma.
- 26 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0305072
Open AccessModes of HIV transmission among young women and their sexual partners in Ukraine
Background: Ukraine has the second-largest HIV epidemic in Europe, with most new cases officially attributed to heterosexual transmission. Indirect evidence suggested substantial HIV transmission from people who inject drugs (PWID) to their sexual partners. This study examined the extent of heterosexual HIV transmission between PWID and non-drug-using adolescent girls and young women (AGYW). Methods: A cross-sectional survey recruited AGYW diagnosed with heterosexually-acquired HIV between 2016 and 2019 in nine regions of Ukraine. AGYW were asked to identify and refer their sexual partners (‘Partners’), who subsequently underwent HIV testing, and, if positive, HCV testing. Both AGYW and Partners completed an interview assessing HIV risk behaviors prior to AGYW’s HIV diagnosis. Results: In August-December 2020, we enrolled 321 AGYW and 64 Partners. Among the Partners, 42% either self-reported IDU or were HCV-positive, indicating an IDU-related mode of HIV transmission. PWID Partners were more likely to report sexually transmitted infections (STI) and had lower educational levels. Of the 62 women who recruited at least one Partner, 40% had a PWID Partner. Within this subgroup, there was a higher prevalence of STIs (52% vs. 24%) and intimate partner violence (36% vs. 3%). Condom use was less common (52% vs. 38% reporting never use), and frequent alcohol or substance use before sex was higher (48% vs 30%) among AGYW with PWID Partner, although this difference did not reach statistical significance. Notably, 52% of women were aware of their Partners’ IDU. Conclusion: At least 40% of heterosexual transmission among AGYW in Ukraine can be linked to PWID partners. Intensified, targeted HIV prevention efforts are essential for key and bridge populations (PWID and their sexual partners), addressing the biological and structural determinants of transmission between key and bridge populations, such as IDU- and HIV status disclosure, STIs, IPV, and stigma.
- Open Access
- 2 November 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (11) , e0000344
Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial
International agencies recommend integrating addiction treatment into primary care for people who inject drugs (PWID) with opioid use disorder (OUD). Empirical data supporting integration that incorporates comprehensive health outcomes, however, are not known. For this randomized controlled trial in Ukraine, adult PWID with OUD were randomized to receive opioid agonist therapy (OAT) in specialty addiction treatment clinics (SATC) or to primary care clinics (PCCs). For those randomized to PCC, they were subsequently allocated to PCCs where clinicians received pay-for-performance (P4P) incentives (PCC with P4P) or not (PCC without P4P). Participating cities had one of each of the three intervention sites to control for geographic variation. Ongoing tele-education specialty training (OAT, HIV, tuberculosis) was provided to all PCCs. While the primary outcome for the parent trial focuses on patient medical record data, this preliminary analysis focuses on assessment of self-reported achievement of nationally recommended quality health indicators (QHIs) which is summed as a composite QHI score. Secondary outcomes included specialty and primary care QHI subscores. This study occurred from 01/20/2018-11/1/2020 with 818 of 990 randomized participants having complete self-reported data for analysis. Relative to SATC (treatment as usual), the mean composite QHI score was 12.7 (95% CI: 10.1–15.3; pClinical trial registration: This trial was registered at clinicaltrials.gov and can be found using the following registration number: NCT04927091.
- 2 November 2022
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (11) , e0000344
Open AccessPreliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial
International agencies recommend integrating addiction treatment into primary care for people who inject drugs (PWID) with opioid use disorder (OUD). Empirical data supporting integration that incorporates comprehensive health outcomes, however, are not known. For this randomized controlled trial in Ukraine, adult PWID with OUD were randomized to receive opioid agonist therapy (OAT) in specialty addiction treatment clinics (SATC) or to primary care clinics (PCCs). For those randomized to PCC, they were subsequently allocated to PCCs where clinicians received pay-for-performance (P4P) incentives (PCC with P4P) or not (PCC without P4P). Participating cities had one of each of the three intervention sites to control for geographic variation. Ongoing tele-education specialty training (OAT, HIV, tuberculosis) was provided to all PCCs. While the primary outcome for the parent trial focuses on patient medical record data, this preliminary analysis focuses on assessment of self-reported achievement of nationally recommended quality health indicators (QHIs) which is summed as a composite QHI score. Secondary outcomes included specialty and primary care QHI subscores. This study occurred from 01/20/2018-11/1/2020 with 818 of 990 randomized participants having complete self-reported data for analysis. Relative to SATC (treatment as usual), the mean composite QHI score was 12.7 (95% CI: 10.1–15.3; pClinical trial registration: This trial was registered at clinicaltrials.gov and can be found using the following registration number: NCT04927091.
- 1 September 2019
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 104, 34-41
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
- 1 September 2019
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 104, 34-41
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
- Open Access
- 8 May 2019
- Published by Publishing house "Grani" in Вісник Академії праці, соціальних відносин і туризму
- No. 1,p. 30-41
ДЕСЯТИРІЧНИЙ ДОСВІД ЗАСТОСУВАННЯ ЛІКУВАННЯ АГОНІСТАМИ ОПІОЇДІВ В УКРАЇНІ. ЩО ДАЛІ? (Частина друга)
Цією статтею автори завершують презентацію десятирічної історії впровадження в Україні підтримувальної терапії агоністами опіоїдів (ПТАО). Аналіз матеріалів низки закордонних і вітчизняних публікацій дозволив перейти до розкриття двох наступних етапів – періодів стагнації та усвідомлення основних проблем. Визначено найголовніші бар’єри впровадження методу (опір органів виконавчої влади та частини професійної спільноти, упереджене ставлення з боку широкого загалу й окремих клієнтів, консервативна позиція представників мас-медіа, застаріла антинаркотична політика, невдалий менеджмент, недостатній рівень професійної підготовки фахівців). Висвітлено організаційні перешкоди лікування агоністами опіоїдів на українських сайтах, складнощі застосування адекватних доз препаратів та психологічні аспекти проведення ПТАО. Матеріал завершено загальними висновками щодо доведеної ефективності методу; потреби в його ширшій імплементації; значущості соціально-психологічної компоненти програм, що має бути реалізована психологами, соціальними працівниками й зосереджена, насамперед, на подолання зовнішньої та внутрішньої стигматизації осіб з опіоїдною залежністю та їхню соціальну реабілітацію. Окреслено потребу в запровадженні спеціалізованої професійної підготовки соціальних працівників для роботи в програмах лікування агоністами опіоїдів.
- 8 May 2019
- Published by Publishing house "Grani" in Вісник Академії праці, соціальних відносин і туризму
- No. 1,p. 30-41
Open AccessДЕСЯТИРІЧНИЙ ДОСВІД ЗАСТОСУВАННЯ ЛІКУВАННЯ АГОНІСТАМИ ОПІОЇДІВ В УКРАЇНІ. ЩО ДАЛІ? (Частина друга)
Цією статтею автори завершують презентацію десятирічної історії впровадження в Україні підтримувальної терапії агоністами опіоїдів (ПТАО). Аналіз матеріалів низки закордонних і вітчизняних публікацій дозволив перейти до розкриття двох наступних етапів – періодів стагнації та усвідомлення основних проблем. Визначено найголовніші бар’єри впровадження методу (опір органів виконавчої влади та частини професійної спільноти, упереджене ставлення з боку широкого загалу й окремих клієнтів, консервативна позиція представників мас-медіа, застаріла антинаркотична політика, невдалий менеджмент, недостатній рівень професійної підготовки фахівців). Висвітлено організаційні перешкоди лікування агоністами опіоїдів на українських сайтах, складнощі застосування адекватних доз препаратів та психологічні аспекти проведення ПТАО. Матеріал завершено загальними висновками щодо доведеної ефективності методу; потреби в його ширшій імплементації; значущості соціально-психологічної компоненти програм, що має бути реалізована психологами, соціальними працівниками й зосереджена, насамперед, на подолання зовнішньої та внутрішньої стигматизації осіб з опіоїдною залежністю та їхню соціальну реабілітацію. Окреслено потребу в запровадженні спеціалізованої професійної підготовки соціальних працівників для роботи в програмах лікування агоністами опіоїдів.